SYK says 2024 guidance unchanged despite supply challenges in key segments
SYK said 2024 guidance remains unchanged despite ongoing supply challenges in peripheral vascular and joint replacement segments. Management cited robust performance in capital and trauma businesses offsetting softness, supporting long-term growth, margin expansion, and share regain.
Guidance for 2024 remains unchanged despite ongoing supply challenges in peripheral vascular and joint replacement segments, while stronger performance in the capital and trauma businesses helps offset the softness. Management said it remains confident in long-term growth, margin expansion and the ability to regain share over time.